Search Results

ImmunoBiochem Corporation announced a multi-target license and option agreement with ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, to advance novel, first-in-class ADCs.

ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics.

The license and option deal, for an undisclosed amount, seeks to develop potentially first-in-class antibody-drug conjugate candidates against different oncology targets.

Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million.

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”) today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024.

Quest Diagnostics, a leader in diagnostic information services, released its 2023 Corporate Responsibility Report.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.

Bruker Corporation announced it will present at the following conferences.

FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions is pleased to provide the following corporate update.

OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.